Advancing Global Health

Gilead recognizes that the development of innovative medicines for life-threatening diseases is only one aspect of improving public health. We also invest in programs that promote prevention, strengthen healthcare infrastructure, and provide education support and financial support to the most vulnerable communities around the world.

By enabling access to medicines, challenging assumptions, fighting stigma and collaborating with partners worldwide, we work not simply to treat some of the world’s most challenging public health threats – but to eliminate them.

Manufacturing of Veklury

Gilead’s Response to COVID-19

We are committed to helping to end the pandemic and have used our decades of experience in treating viral diseases to advance our antiviral medicine for COVID-19.

We are studying ways to enhance the disruption of viral replication in order to advance novel treatments to help more people. Our efforts include both expanding our internal research programs and working with the broader scientific community.

Helping Eliminate Chronic Hepatitis C Worldwide

The WHO has set the goal of eliminating viral hepatitis worldwide by 2030. Through awareness, screening and care, we’re helping governments, patients and payers in efforts to eliminate the chronic hepatitis C virus (HCV) and end the disease.

Infographic stating that of every 100 people infected with hepatitis C, 70 will develop chronic liver disease